Recent from talks
Perampanel
Knowledge base stats:
Talk channels stats:
Members stats:
Perampanel
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures. Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.
Perampanel was approved in 2012, and as of 2016[update], its optimal role in the treatment of epilepsy relative to other drugs is not clear. It is the first anti-epileptic drug in the class of selective non-competitive antagonist of AMPA receptors.
The US prescribing information has a boxed warning that perampanel may cause serious psychiatric and behavioral changes; it may cause homicidal or suicidal thoughts. Other side effects have included dizziness, somnolence, vertigo, aggression, anger, loss of coordination, blurred vision, irritability, and slurred speech. Perampanel reduced the effectiveness of levonorgestrel oral contraceptives by about 40%. Women who may get pregnant should not take it as studies in animals show it may harm a fetus. Perampanel is liable to be abused; very high doses produced euphoria responses similar to ketamine. It is designated as a Schedule III controlled substance by the US Drug Enforcement Administration. Perampanel is authorized as a generic medication.
Perampanel is used in addition to other drugs to treat partial seizures and generalized tonic–clonic seizures for people older than twelve years.
In the US, perampanel is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four years of age and older; and for adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in people with epilepsy aged twelve years of age and older.
In the EU, perampanel is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in people aged twelve years of age and older with epilepsy; and for the adjunctive treatment of primary generalized tonic-clonic seizures in people aged twelve years of age and older with idiopathic generalized epilepsy.
Based on animal data, perampanel may cause fetal harm; it is not recommended for women of child-bearing age not taking contraception.
People with severe liver impairment or severe kidney disease, including those on dialysis, should not take perampanel.
Hub AI
Perampanel AI simulator
(@Perampanel_simulator)
Perampanel
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures. Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.
Perampanel was approved in 2012, and as of 2016[update], its optimal role in the treatment of epilepsy relative to other drugs is not clear. It is the first anti-epileptic drug in the class of selective non-competitive antagonist of AMPA receptors.
The US prescribing information has a boxed warning that perampanel may cause serious psychiatric and behavioral changes; it may cause homicidal or suicidal thoughts. Other side effects have included dizziness, somnolence, vertigo, aggression, anger, loss of coordination, blurred vision, irritability, and slurred speech. Perampanel reduced the effectiveness of levonorgestrel oral contraceptives by about 40%. Women who may get pregnant should not take it as studies in animals show it may harm a fetus. Perampanel is liable to be abused; very high doses produced euphoria responses similar to ketamine. It is designated as a Schedule III controlled substance by the US Drug Enforcement Administration. Perampanel is authorized as a generic medication.
Perampanel is used in addition to other drugs to treat partial seizures and generalized tonic–clonic seizures for people older than twelve years.
In the US, perampanel is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four years of age and older; and for adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in people with epilepsy aged twelve years of age and older.
In the EU, perampanel is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in people aged twelve years of age and older with epilepsy; and for the adjunctive treatment of primary generalized tonic-clonic seizures in people aged twelve years of age and older with idiopathic generalized epilepsy.
Based on animal data, perampanel may cause fetal harm; it is not recommended for women of child-bearing age not taking contraception.
People with severe liver impairment or severe kidney disease, including those on dialysis, should not take perampanel.
Recent media